Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy
Наночастицы оксида марганца как контрастные агенты для мультимодальной визуализации и терапии опухолей методом МРТ
2019-10-01
SCID: 54.1/snyxaaen
Discuss with AI
MRI contrast agentsmanganese oxide nanoparticlesmultimodal tumor imagingphotothermal and photodynamic therapytumor microenvironment-responsive therapy
Figures from the paper
Abstract (AI)
Abstract: Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO 2 , Mn 3 O 4 , and MnO x ) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies. Keywords: manganese oxide nanoparticles, MRI, multimodal imaging, contrast agent, tumor therapy
Key Findings
1
Compared with short-circulating Mn(II) chelates, colloidal manganese oxide nanoparticles offer size-controlled circulation times that may improve imaging performance.
2
Manganese oxide nanoparticles support multimodal tumor imaging and therapy, including photothermal and photodynamic treatments.
3
Manganese oxide nanoparticles, including MnO, MnO₂, Mn₃O₄, and MnOₓ, provide bright T1-weighted MRI contrast for tumor detection and diagnosis.
4
Manganese-based contrast agents are highlighted as promising alternatives to gadolinium agents because of better biocompatibility and reduced concerns about renal fibrosis.
5
The review covers manganese oxide nanoparticle toxicity, biodistribution, and tumor microenvironment-responsive enhancement of chemotherapy and radiotherapy.
Research Object
manganese oxide nanoparticles used as MRI contrast agents in tumors
Research Subject
their MRI contrast performance and tumor-targeted multimodal imaging and therapy, including toxicity, biodistribution, tumor-microenvironment responsiveness, and enhancement of chemotherapy, radiotherapy, photothermal therapy, and photodynamic therapy
Publication Details
Publication Date
2019-10-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest